Outlook down since 1 PM, expected “impacted” through the night
Tomorrow's inbox: 300 emails, 3 that matter, and 40 reply-alls asking if anyone else's Outlook is down
@seanmmcbride reduction in Outlook volume appears to be budget-neutral
communication redirected to secure chat, consistent with alternative pathway utilization
Target-trial emulation is still observational research. Treatment selection isn't random.
Same core concern as other observational comparisons: unmeasured confounding, particularly confounding by indication.
Better design helps, but doesn't replace randomization.
Great breakdown👇
Clean randomized signal for pembro + MDT in oligometastatic RCC:
RFS 11 → 25.4 mo (HR 0.47), 72% got SABR
Next Q: patterns of recurrence after MDT ± pembro
#radonc#ESMO26
PE-PE is a fantastic study, giving us randomized data on adding pembrolizumab to MDT in oligometastatic RCC!
Phase II, open-label, multicenter trial: 85 pts with prior nephrectomy and ≤3 mets within 5y of nephrectomy or previous metastasectomy, all amenable to surgery or SABR. Randomized 2:1 favoring pembro: MDT alone (n=29) vs pembro + MDT (n=56).
Pembro 400 mg q6w x9c (1y). First dose BEFORE MDT; registry specifies MDT on C1d21-42.
At MFU 17.5 mo, median RFS was 11→ 25.4 mo (HR 0.47, 95CI 0.24-0.92, p=0.024), MDT alone→ pembro + MDT. 35 RFS events, 16→ 19.
SABR 72→ 73%; surgery 28→ 23%. SABR dose/fx and per-site data weren't reported. I'd like to see those details along with local vs distant relapse.
Any AE 21→ 80%; G3 AEs 3→ 7%. The 21% control rate is with no study systemic therapy. Pembro-related AEs occurred in 59%, including G3 in 2 pts; no G4/5 pembro-related events were reported. Four pts stopped pembro for AEs.
Both groups received MDT, so the randomized question is what pembro adds. This doesn't establish the benefit of MDT itself or RT-ICI synergy. With 1 death/arm and no QoL results reported, an OS/QoL benefit remains unestablished.
I'd also like the prior systemic therapy history and the timing/burden at first metastatic presentation. The eligibility window alone doesn't tell us whether these pts were oligometastatic from the outset.
Congratulations to the investigators on this important work!
https://t.co/i8P1uvW9y4
#radonc #ESMO26 #RCC
Honored to be elected to the @nnecos_oncology Board. NNECOS brings together oncology across ME, NH, and VT & gives our trainees a real regional stage. Looking forward to the work ahead with colleagues across the region.
2026 NNECOS BOD Election Results
Thanks to all who participated in the 2026 NNECOS Board of Directors Election, as candidates and as voters. We are pleased to announce the following individuals have been elected/reelected to a three year term on the board, which begins January 1.
ENZARAD @JCO | ANZUP 1303
n=802 | mFU 92 mo
ADT+RT ± enza 24 mo vs NSAA 6 mo
MFS/OS overall ⛔️
pelvic RT subgroup 🎯 HR 0.47
no Decipher/PAM50 - still unclear who benefits from intensification
https://t.co/DBtY2lBiWq
🚨📣📣 #ESMO26 presidential: @niazi_Dr7 Adding darolutamide to ADT + RT dramatically ⬇️ risk of metastasis or death in high-risk localized prostate cancer. Phase 3 DASL-HiCaP = 58% ⬇️ in MFS (HR 0.42) + early OS signal (HR 0.88). #ProstateCancer#RadOnc#pcsm@ChrisSweens1
At #ASTRO26, we are proud to welcome so many Yale attendees, including our current residents and the alumni of our Radiation Oncology Residency Program @YaleRadOnc, all representing @YaleMed@SmilowCancer@YNHH and advancing the field of radiation oncology. @ASTRO_org@OncoAlert
Grateful to organizers for PRO 11 @ #ASTRO26:
Trial design keeps getting more complicated. Ph II data, de-escalation/omission studies, new tech routinely reported as practice-changing.
Outstanding talks on how to read that evidence and which results should change practice!
#ASTRO26 climate change, IT risk, and other system shocks make this more relevant every year. The real value here was in the stories: lessons for prevention and prep, and what we can actually do to safeguard RT when the next disruption hits.
Thank you to this panel!
This Sunday!
WHEN DISASTER STRIKES
⛈️ 🌬️ 🌀 🔥
Safeguarding Radiotherapy's Value and Continuity Across Catastrophic Events
#ASTRO26 Annual Meeting
Educational Session 8244
📆 Sunday 9/27/2026
⏰ 2:30 PM - 4:00 PM
📍 Room 257
Excited to see you at this session.
Long-term PACE-A data at #ASTRO26 (van As LBA32, Yasar LBA10): the first randomized comparison of prostatectomy vs SBRT, 36.25 Gy in 5 fractions.
These are contemporary surgical data: all prostatectomies were laparoscopic, 84% robotic.
Using ≥1 pad/day, RP vs SBRT:
• 2 years: 50% vs 7%
• 5 years: 48% vs 8%
Sexual function at 5 years:
• EPIC sexual domain: 62→17 after RP vs 79→58 after SBRT
• Median IIEF-5: 5 vs 19
Important caveats: as-treated analysis, approximately 60% PRO completion at 5 years, baseline sexual function imbalance, and enrollment of 123 of a planned 234 patients.
Biochemical control looks similar through 8 years, but 13 events cannot establish equivalence.
For shared decision-making, these are numbers I’d want patients to see. Every patient considering prostatectomy should have the opportunity to meet with a radiation oncologist before choosing treatment.
#RadOnc #PCSM
#ASTRO26@nickva1 presents 5 yr data of PACE-A: SBRT v RP
no differences in clinical outcomes
use of =1 urinary pad 8.3% SBRT V 48% RP
Low GI/GU events <%4 each arms
#ASTRO26 A071801
1-4 BMs
SRS (12-20Gy by volume) or fSRS (27Gy/3 <30cc or 30Gy/5 >30cc) after resection
fSRS ➡️ superior surgical bed control
no differences in RN or QoL